Drugs / 4-[18F]Fluoro-1-Naphthol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05335811 | Oct 2022 → Aug 2028 expected | endocrine gland neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07325253 | Nov 2025 → Jan 2028 expected | chronic graft versus host disease | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-[18F]Fluoro-1-Naphthol | “4-\[18F\]Fluoro-1-Naphthol (also called \[18F\]4FN)” NCT07325253 ↗ |
| Known as | [18F]4FN | “4-\[18F\]Fluoro-1-Naphthol (also called \[18F\]4FN)” NCT07325253 ↗ |
| Modality | Diagnostic / imaging agent | “novel PET agent for imaging inflammation” NCT05335811 ↗ |
| Route | Intravenous | “By vein (IV)” NCT05335811 ↗ |